Promising combo for tough breast cancer hits roadblock
Disease control
Terminated
This study tested a new drug (LY2780301) combined with standard chemotherapy (paclitaxel) in people with advanced HER2-negative breast cancer that had spread or couldn't be removed by surgery. The goal was to find the safest dose and see if the combination could shrink tumors. Th…
Phase: PHASE1, PHASE2 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated May 01, 2026 15:57 UTC